Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know

Apellis Pharmaceuticals -1.64%

Apellis Pharmaceuticals

APLS

41.31

-1.64%

During the last three months, 16 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ:APLS), revealing diverse outlooks from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 10 3 3 0 0
Last 30D 0 1 0 0 0
1M Ago 4 1 1 0 0
2M Ago 4 1 1 0 0
3M Ago 2 0 1 0 0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $74.75, a high estimate of $106.00, and a low estimate of $42.00. Observing a 5.28% increase, the current average has risen from the previous average price target of $71.00.

price target chart

Understanding Analyst Ratings: A Comprehensive Breakdown

A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Justin Kim Oppenheimer Raises Outperform $79.00 $75.00
Joseph Stringer Needham Raises Buy $75.00 $70.00
Colleen Kusy Baird Raises Outperform $81.00 $71.00
Douglas Tsao HC Wainwright & Co. Raises Buy $92.00 $82.00
Laura Chico Wedbush Raises Neutral $60.00 $39.00
Steven Seedhouse Raymond James Raises Strong Buy $106.00 $67.00
Salveen Richter Goldman Sachs Raises Buy $90.00 $65.00
Yigal Nochomovitz Citigroup Lowers Buy $67.00 $70.00
Justin Kim Oppenheimer Lowers Outperform $75.00 $88.00
Steven Seedhouse Raymond James Lowers Strong Buy $67.00 $93.00
Joseph Stringer Needham Lowers Buy $56.00 $63.00
Derek Archila Wells Fargo Lowers Equal-Weight $54.00 $67.00
Tazeen Ahmad B of A Securities Raises Buy $85.00 $52.00
Salveen Richter Goldman Sachs Announces Buy $74.00 -
Graig Suvannavejh Mizuho Announces Neutral $42.00 -
Steven Seedhouse Raymond James Raises Strong Buy $93.00 $92.00

Key Insights:

  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Apellis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
  • Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for Apellis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Apellis Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Apellis Pharmaceuticals analyst ratings.

Get to Know Apellis Pharmaceuticals Better

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Financial Milestones: Apellis Pharmaceuticals's Journey

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Apellis Pharmaceuticals displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 400.54%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Apellis Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -127.03%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -48.55%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -16.18%, the company may face hurdles in achieving optimal financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.

The Core of Analyst Ratings: What Every Investor Should Know

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via